Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | FPR1 | P21462 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381061 | 1.00 | FPR2 (0.51) | FPR2MMP2MMP9MMP1MMP3 | |
| SCHEMBL28059810 | 0.83 | KDM4E (0.44) | FPR2MMP2MMP9MMP1MMP3 | |
| SCHEMBL7436999 | 0.82 | CA12 (0.50) | SMN1; SMN2KDM4EALDH1A1CA12MMP8 | |
| SCHEMBL16057214 | 0.82 | CA12 (0.47) | MMP2ALDH1A1CA12MAOAMAOB | |
| SCHEMBL7089012 | 0.82 | CA12 (0.47) | MMP2ALDH1A1CA12MAOAMAOB | |
| SCHEMBL7028109 | 0.82 | CA12 (0.47) | MMP2ALDH1A1CA12MAOAMAOB | |
| SCHEMBL29173167 | 0.82 | CA12 (0.50) | SMN1; SMN2KDM4EALDH1A1CA12MMP8 | |
| SCHEMBL3078749 | 0.82 | CA12 (0.50) | SMN1; SMN2KDM4EALDH1A1CA12MMP8 | |
| SCHEMBL33927 | 0.81 | TDP1 (0.56) | SMN1; SMN2ALDH1A1CA12MEN1KMT2A | |
| SCHEMBL33928 | 0.81 | TDP1 (0.56) | SMN1; SMN2ALDH1A1CA12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119410678-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | claimed |
| CN-112313336-B | Method for optimizing antibody expression | AMBRX公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4402259-A2 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | ABSCI Corporation (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2023044431-A2 | COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS | Absci Corporation (US) | 2023-03-23 | — | — | WO | claimed |
| EP-3788149-A1 | A METHOD FOR OPTIMIZING ANTIBODY EXPRESSION | Ambrx, Inc. (US) | 2021-03-10 | — | — | EP | claimed |
| CN-110506049-A | For combining the peptide ligand of MT1-MMP | BICYCLETX LTD | 2019-11-26 | — | — | CN | claimed |
| CN-110437297-A | The inhibitor of farnesoid X receptor and purposes in medicine | US HEALTH | 2019-11-12 | — | — | CN | claimed |
| CN-105593237-B | Inhibitors of farnesoid X receptor and use in medicine | 美国卫生和人力服务部 | 2019-06-04 | — | — | CN | claimed |
| CN-109414510-A | Bicyclic peptide-the toxin-conjugate of MT1-MMP specificity | 拜斯科阿迪有限公司 | 2019-03-01 | — | — | CN | claimed |
| US-20180085479-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2018-03-29 | — | — | US | claimed |
| CN-104350064-A | Modified kisspeptin peptides and uses thereof | YEDA RES & DEV | 2015-02-11 | — | — | CN | claimed |
| US-20140227175-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2014-08-14 | — | — | US | claimed |
| EP-2723387-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. Stefan Institute (SI) | 2014-04-30 | — | — | EP | claimed |
| CN-101878303-B | Directed evolution using proteins comprising unnatural amino acids | SCRIPPS RESEARCH INST | 2014-04-30 | — | — | CN | claimed |
| CN-103289960-A | Expanding the eukaryotic genetic code | SCRIPPS RESEARCH INST | 2013-09-11 | — | — | CN | claimed |
| CN-103215227-A | Expanding the eukaryotic genetic code | SCRIPPS RESEARCH INST | 2013-07-24 | — | — | CN | claimed |
| CN-103215228-A | Expanding the eukaryotic genetic code | SCRIPPS RESEARCH INST | 2013-07-24 | — | — | CN | claimed |
| CN-101223272-B | Expanding the eukaryotic genetic code | SCRIPPS RESEARCH INST | 2013-04-03 | — | — | CN | claimed |
| WO-2012175223-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | J. STEFAN INSTITUTE (SI) | 2012-12-27 | — | — | WO | claimed |
| CN-101939410-A | In vivo unnatural amino acid expression in methylotrophic yeast Pichia pastoris | SCRIPPS RESEARCH INST | 2011-01-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227175-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | CTSB, CTSV, CTSE | FPR2 519/4885MMP2 118/4885MMP9 159/4885 |
| US-20180085479-A1 | CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE | CTSB, CTSV, CTSE | FPR2 519/4885MMP2 118/4885MMP9 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.